A citation-based method for searching scientific literature

Gregory D Jones, Raul Caso, Kay See Tan, Brooke Mastrogiacomo, Francisco Sanchez-Vega, Yuan Liu, James G Connolly, Yonina R Murciano-Goroff, Matthew J Bott, Prasad S Adusumilli, Daniela Molena, Gaetano Rocco, Valerie W Rusch, Smita Sihag, Sandra Misale, Rona Yaeger, Alexander Drilon, Kathryn C Arbour, Gregory J Riely, Neal Rosen, Piro Lito, Haiying Zhang, David C Lyden, Charles M Rudin, David R Jones, Bob T Li, James M Isbell. Clin Cancer Res 2021
Times Cited: 2







List of co-cited articles
7 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.
Mark G Kris, Bruce E Johnson, Lynne D Berry, David J Kwiatkowski, A John Iafrate, Ignacio I Wistuba, Marileila Varella-Garcia, Wilbur A Franklin, Samuel L Aronson, Pei-Fang Su,[...]. JAMA 2014
955
50

Liquid Biopsy: From Discovery to Clinical Application.
Catherine Alix-Panabières, Klaus Pantel. Cancer Discov 2021
26
50

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.
Tetsuya Mitsudomi, Satoshi Morita, Yasushi Yatabe, Shunichi Negoro, Isamu Okamoto, Junji Tsurutani, Takashi Seto, Miyako Satouchi, Hirohito Tada, Tomonori Hirashima,[...]. Lancet Oncol 2010
50

Genome-wide cell-free DNA fragmentation in patients with cancer.
Stephen Cristiano, Alessandro Leal, Jillian Phallen, Jacob Fiksel, Vilmos Adleff, Daniel C Bruhm, Sarah Østrup Jensen, Jamie E Medina, Carolyn Hruban, James R White,[...]. Nature 2019
224
50

Genomic assessment distinguishes intrapulmonary metastases from synchronous primary lung cancers.
Erin M Corsini, Jinliang Wang, Chia-Chin Wu, Junya Fujimoto, Marcelo V Negrao, Runzhe Chen, Kelly Quek, Kyle G Mitchell, Chi-Wan B Chow, Latasha Little,[...]. J Thorac Dis 2020
1
100

Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer.
Isaac Garcia-Murillas, Gaia Schiavon, Britta Weigelt, Charlotte Ng, Sarah Hrebien, Rosalind J Cutts, Maggie Cheang, Peter Osin, Ashutosh Nerurkar, Iwanka Kozarewa,[...]. Sci Transl Med 2015
603
50

Outcomes after neoadjuvant or adjuvant chemotherapy for cT2-4N0-1 non-small cell lung cancer: A propensity-matched analysis.
Whitney S Brandt, Wanpu Yan, Jian Zhou, Kay See Tan, Joseph Montecalvo, Bernard J Park, Prasad S Adusumilli, James Huang, Matthew J Bott, Valerie W Rusch,[...]. J Thorac Cardiovasc Surg 2019
15
50

Using Genomics to Differentiate Multiple Primaries From Metastatic Lung Cancer.
Stephen J Murphy, Faye R Harris, Farhad Kosari, Simone Barreto Siqueira Parrilha Terra, Aqsa Nasir, Sarah H Johnson, Vishnu Serla, James B Smadbeck, Geoffrey C Halling, Giannoula Karagouga,[...]. J Thorac Oncol 2019
19
50

Targeted Therapies in Early Stage NSCLC: Hype or Hope?
Alex Friedlaender, Alfredo Addeo, Alessandro Russo, Vanesa Gregorc, Diego Cortinovis, Christian D Rolfo. Int J Mol Sci 2020
10
50

Cell-free DNA Comprises an In Vivo Nucleosome Footprint that Informs Its Tissues-Of-Origin.
Matthew W Snyder, Martin Kircher, Andrew J Hill, Riza M Daza, Jay Shendure. Cell 2016
509
50

Solid Predominant Histologic Subtype in Resected Stage I Lung Adenocarcinoma Is an Independent Predictor of Early, Extrathoracic, Multisite Recurrence and of Poor Postrecurrence Survival.
Hideki Ujiie, Kyuichi Kadota, Jamie E Chaft, Daniel Buitrago, Camelia S Sima, Ming-Ching Lee, James Huang, William D Travis, Nabil P Rizk, Charles M Rudin,[...]. J Clin Oncol 2015
115
50

The Underlying Tumor Genomics of Predominant Histologic Subtypes in Lung Adenocarcinoma.
Raul Caso, Francisco Sanchez-Vega, Kay See Tan, Brooke Mastrogiacomo, Jian Zhou, Gregory D Jones, Bastien Nguyen, Nikolaus Schultz, James G Connolly, Whitney S Brandt,[...]. J Thorac Oncol 2020
13
50

APOBEC Enzymes: Mutagenic Fuel for Cancer Evolution and Heterogeneity.
Charles Swanton, Nicholas McGranahan, Gabriel J Starrett, Reuben S Harris. Cancer Discov 2015
234
50

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.
Makoto Maemondo, Akira Inoue, Kunihiko Kobayashi, Shunichi Sugawara, Satoshi Oizumi, Hiroshi Isobe, Akihiko Gemma, Masao Harada, Hirohisa Yoshizawa, Ichiro Kinoshita,[...]. N Engl J Med 2010
50

The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival.
Arne Warth, Thomas Muley, Michael Meister, Albrecht Stenzinger, Michael Thomas, Peter Schirmacher, Philipp A Schnabel, Jan Budczies, Hans Hoffmann, Wilko Weichert. J Clin Oncol 2012
446
50

Targeted Next-Generation Sequencing Analysis for Recurrence in Early-Stage Lung Adenocarcinoma.
In Ae Kim, Jae Young Hur, Hee Joung Kim, Jung Hoon Park, Jae Joon Hwang, Song Am Lee, Seung Eun Lee, Wan Seop Kim, Kye Young Lee. Ann Surg Oncol 2021
6
50

Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
Jean-Charles Soria, Yuichiro Ohe, Johan Vansteenkiste, Thanyanan Reungwetwattana, Busyamas Chewaskulyong, Ki Hyeong Lee, Arunee Dechaphunkul, Fumio Imamura, Naoyuki Nogami, Takayasu Kurata,[...]. N Engl J Med 2018
50

The Evolving Landscape of Resistance to Osimertinib.
Adam J Schoenfeld, Helena A Yu. J Thorac Oncol 2020
14
50

Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer.
Scott Gettinger, Jungmin Choi, Katherine Hastings, Anna Truini, Ila Datar, Ryan Sowell, Anna Wurtz, Weilai Dong, Guoping Cai, Mary Ann Melnick,[...]. Cancer Discov 2017
249
50

Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
Solange Peters, D Ross Camidge, Alice T Shaw, Shirish Gadgeel, Jin S Ahn, Dong-Wan Kim, Sai-Hong I Ou, Maurice Pérol, Rafal Dziadziuszko, Rafael Rosell,[...]. N Engl J Med 2017
980
50

Understanding and targeting resistance mechanisms in NSCLC.
Julia Rotow, Trever G Bivona. Nat Rev Cancer 2017
352
50

Expansion and Activation of CD103(+) Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition.
Hélène Salmon, Juliana Idoyaga, Adeeb Rahman, Marylène Leboeuf, Romain Remark, Stefan Jordan, Maria Casanova-Acebes, Makhzuna Khudoynazarova, Judith Agudo, Navpreet Tung,[...]. Immunity 2016
465
50

TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients.
Joe-Marc Chauvin, Ornella Pagliano, Julien Fourcade, Zhaojun Sun, Hong Wang, Cindy Sander, John M Kirkwood, Tseng-hui Timothy Chen, Mark Maurer, Alan J Korman,[...]. J Clin Invest 2015
347
50

Overcoming T cell exhaustion in infection and cancer.
Kristen E Pauken, E John Wherry. Trends Immunol 2015
519
50

The great escape: tumour cell plasticity in resistance to targeted therapy.
Soufiane Boumahdi, Frederic J de Sauvage. Nat Rev Drug Discov 2020
118
50

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade.
Nicholas McGranahan, Andrew J S Furness, Rachel Rosenthal, Sofie Ramskov, Rikke Lyngaa, Sunil Kumar Saini, Mariam Jamal-Hanjani, Gareth A Wilson, Nicolai J Birkbak, Crispin T Hiley,[...]. Science 2016
50

Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer.
Kroopa Joshi, Marc Robert de Massy, Mazlina Ismail, James L Reading, Imran Uddin, Annemarie Woolston, Emine Hatipoglu, Theres Oakes, Rachel Rosenthal, Thomas Peacock,[...]. Nat Med 2019
64
50

Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration.
Alexander Drilon, Jeffrey W Clark, Jared Weiss, Sai-Hong Ignatius Ou, D Ross Camidge, Benjamin J Solomon, Gregory A Otterson, Liza C Villaruz, Gregory J Riely, Rebecca S Heist,[...]. Nat Med 2020
100
50

Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study.
Scott Gettinger, Leora Horn, David Jackman, David Spigel, Scott Antonia, Matthew Hellmann, John Powderly, Rebecca Heist, Lecia V Sequist, David C Smith,[...]. J Clin Oncol 2018
318
50

The National Lung Matrix Trial of personalized therapy in lung cancer.
Gary Middleton, Peter Fletcher, Sanjay Popat, Joshua Savage, Yvonne Summers, Alastair Greystoke, David Gilligan, Judith Cave, Noelle O'Rourke, Alison Brewster,[...]. Nature 2020
33
50

The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients.
Vyara Matson, Jessica Fessler, Riyue Bao, Tara Chongsuwat, Yuanyuan Zha, Maria-Luisa Alegre, Jason J Luke, Thomas F Gajewski. Science 2018
909
50

Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial.
Ahmet Sezer, Saadettin Kilickap, Mahmut Gümüş, Igor Bondarenko, Mustafa Özgüroğlu, Miranda Gogishvili, Haci M Turk, Irfan Cicin, Dmitry Bentsion, Oleg Gladkov,[...]. Lancet 2021
35
50

Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma.
Suzanne George, Diana Miao, George D Demetri, Dennis Adeegbe, Scott J Rodig, Sachet Shukla, Mikel Lipschitz, Ali Amin-Mansour, Chandrajit P Raut, Scott L Carter,[...]. Immunity 2017
227
50

Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial.
Robert J Motzer, Paul B Robbins, Thomas Powles, Laurence Albiges, John B Haanen, James Larkin, Xinmeng Jasmine Mu, Keith A Ching, Motohide Uemura, Sumanta K Pal,[...]. Nat Med 2020
39
50

TIGIT: A Key Inhibitor of the Cancer Immunity Cycle.
Nicholas A Manieri, Eugene Y Chiang, Jane L Grogan. Trends Immunol 2017
141
50

Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies.
Tianhong Li, Hsing-Jien Kung, Philip C Mack, David R Gandara. J Clin Oncol 2013
300
50

Emerging role of PTEN loss in evasion of the immune response to tumours.
Thiago Vidotto, Camila Morais Melo, Erick Castelli, Madhuri Koti, Rodolfo Borges Dos Reis, Jeremy A Squire. Br J Cancer 2020
18
50

Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution.
Nicholas McGranahan, Rachel Rosenthal, Crispin T Hiley, Andrew J Rowan, Thomas B K Watkins, Gareth A Wilson, Nicolai J Birkbak, Selvaraju Veeriah, Peter Van Loo, Javier Herrero,[...]. Cell 2017
424
50

Neutralizing tumor-promoting chronic inflammation: a magic bullet?
Lisa M Coussens, Laurence Zitvogel, A Karolina Palucka. Science 2013
662
50

Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial.
Tina Cascone, William N William, Annikka Weissferdt, Cheuk H Leung, Heather Y Lin, Apar Pataer, Myrna C B Godoy, Brett W Carter, Lorenzo Federico, Alexandre Reuben,[...]. Nat Med 2021
29
50

Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer.
Shirish Gadgeel, Delvys Rodríguez-Abreu, Giovanna Speranza, Emilio Esteban, Enriqueta Felip, Manuel Dómine, Rina Hui, Maximilian J Hochmair, Philip Clingan, Steven F Powell,[...]. J Clin Oncol 2020
158
50

Genetic basis for clinical response to CTLA-4 blockade in melanoma.
Alexandra Snyder, Vladimir Makarov, Taha Merghoub, Jianda Yuan, Jesse M Zaretsky, Alexis Desrichard, Logan A Walsh, Michael A Postow, Phillip Wong, Teresa S Ho,[...]. N Engl J Med 2014
50

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.
Roy S Herbst, Jean-Charles Soria, Marcin Kowanetz, Gregg D Fine, Omid Hamid, Michael S Gordon, Jeffery A Sosman, David F McDermott, John D Powderly, Scott N Gettinger,[...]. Nature 2014
50

Neoantigen-directed immune escape in lung cancer evolution.
Rachel Rosenthal, Elizabeth Larose Cadieux, Roberto Salgado, Maise Al Bakir, David A Moore, Crispin T Hiley, Tom Lund, Miljana Tanić, James L Reading, Kroopa Joshi,[...]. Nature 2019
269
50

PD-1 blockade induces responses by inhibiting adaptive immune resistance.
Paul C Tumeh, Christina L Harview, Jennifer H Yearley, I Peter Shintaku, Emma J M Taylor, Lidia Robert, Bartosz Chmielowski, Marko Spasic, Gina Henry, Voicu Ciobanu,[...]. Nature 2014
50

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.
Robert J Motzer, Nizar M Tannir, David F McDermott, Osvaldo Arén Frontera, Bohuslav Melichar, Toni K Choueiri, Elizabeth R Plimack, Philippe Barthélémy, Camillo Porta, Saby George,[...]. N Engl J Med 2018
50

Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC.
Roy S Herbst, Giuseppe Giaccone, Filippo de Marinis, Niels Reinmuth, Alain Vergnenegre, Carlos H Barrios, Masahiro Morise, Enriqueta Felip, Zoran Andric, Sarayut Geater,[...]. N Engl J Med 2020
150
50

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
Julie Brahmer, Karen L Reckamp, Paul Baas, Lucio Crinò, Wilfried E E Eberhardt, Elena Poddubskaya, Scott Antonia, Adam Pluzanski, Everett E Vokes, Esther Holgado,[...]. N Engl J Med 2015
50

A novel human IL-2 mutein with minimal systemic toxicity exerts greater antitumor efficacy than wild-type IL-2.
Xi Chen, Xiaojie Ai, Chunlian Wu, Heyong Wang, Gang Zeng, Peixin Yang, Gentao Liu. Cell Death Dis 2018
4
50


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.